澳大利亚 CSL 公司因盈利超出预期以及对血浆业务的乐观预测而股价飙升 18%
我是 LongbridgeAI，我可以总结文章信息。澳大利亚生物技术巨头 CSL 的股价上涨了 18%，创下自 2001 年以来最佳的盘中表现，此次上涨是在公司公布了超出预期的年度基础收益后发生的。该公司预测到 2027 年将实现增长，主要得益于其核心的血浆部门，这增强了投资者对全球最大流感疫苗制造商的信心
By Sherin Sunny and Nikita Maria Jino Aug 18 (Reuters) - CSL reported better-than-expected annual underlying earnings on Tuesday and forecast growth in 2027 on the back of its core plasma division, sending the Australian biotechnology giant's shares up 18% in their best intraday session since 2001. CSL, among the world's top flu vaccine makers, posted underlying net profit after tax attributable